Press Release Sep 19 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
NATCO Pharma Limited has issued a press release regarding a court approval for the launch of Chlorantraniliprole (CTPR) and its formulations. The Delhi High Court has allowed NATCO to proceed with the launch using a non-infringing process. NATCO is the first company in India to receive registration approval for the indigenous manufacture of CTPR. NATCO plans to launch its products shortly following this approval.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from NATCO Pharma
- Press Release Aug 17 2022
- NATCO records INR 918.9 Crore consolidated revenue and INR 320.4 Crore of profit, after tax, for the First Quarter, FY2022-23
- Press Release Jul 25 2022
- NATCO Announces Launch of First Generic Version of Nexavar (Sorafenib) Tablets in the U.S. Market
- Press Release Jun 01 2022
Later from NATCO Pharma
- Press Release Sep 24 2022
- Press Release Oct 04 2022
- Press Release Oct 21 2022
- Press Release Nov 09 2022
- Press Release Nov 12 2022
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma